{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Nasseri Moghaddam Z"],"funding":["Intramural NIH HHS"],"pubmed_abstract":["Creatine transporter (CTD) and guanidinoacetate methyltransferase (GAMT) deficiencies are rare inborn errors of creatine metabolism, resulting in cerebral creatine deficiency. Patients commonly exhibit intellectual and developmental disabilities, often accompanied by behavior problems, delayed speech, seizures, and motor impairments. There is currently no efficacious treatment for CTD, while the current management for GAMT requires lifelong treatment with a protein restricted diet and intake of high amounts of oral supplements. Efforts to develop effective, sustainable treatments for these disorders are limited by the lack of clinical and patient-derived meaningful outcomes. A core outcome set (COS) can facilitate consensus about outcomes for inclusion in studies. Unfortunately, patient an"],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2024.09.06.24313213"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11451665"],"repository":["biostudies-literature"],"pubmed_title":["Establishing a Core Outcome Set for Creatine Transporter Deficiency and Guanidinoacetate Methyltransferase Deficiency."],"pmcid":["PMC11451665"],"funding_grant_id":["ZIC MH002961"],"pubmed_authors":["Miller JS","Longo N","Schulze A","Young SP","Britz J","Wallis H","Potter BK","Baker SA","Cafferty R","Thurm A","Williams KF","Bilder DA","Tiller BH","Salomons GS","Lipshutz GS","Selucky T","Bogar R","Li J","Stockler-Ipsiroglu S","Graham C","Coller DP","Hall V","Reinhardt EK","Nasseri Moghaddam Z","Wheaton CP","Smith M","Mercimek-Andrews S","DeGrauw TJ","Pasquali M","Balog S"],"additional_accession":[]},"is_claimable":false,"name":"Establishing a Core Outcome Set for Creatine Transporter Deficiency and Guanidinoacetate Methyltransferase Deficiency.","description":"Creatine transporter (CTD) and guanidinoacetate methyltransferase (GAMT) deficiencies are rare inborn errors of creatine metabolism, resulting in cerebral creatine deficiency. Patients commonly exhibit intellectual and developmental disabilities, often accompanied by behavior problems, delayed speech, seizures, and motor impairments. There is currently no efficacious treatment for CTD, while the current management for GAMT requires lifelong treatment with a protein restricted diet and intake of high amounts of oral supplements. Efforts to develop effective, sustainable treatments for these disorders are limited by the lack of clinical and patient-derived meaningful outcomes. A core outcome set (COS) can facilitate consensus about outcomes for inclusion in studies. Unfortunately, patient an","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-04-08T18:48:22.823Z","creation":"2025-04-21T21:48:59.331Z"},"accession":"S-EPMC11451665","cross_references":{"pubmed":["39371127"],"doi":["10.1101/2024.09.06.24313213"]}}